Arax Advisory Partners Has $1.87 Million Stock Holdings in Amgen Inc. $AMGN

Arax Advisory Partners increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 88.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,710 shares of the medical research company’s stock after buying an additional 2,676 shares during the period. Arax Advisory Partners’ holdings in Amgen were worth $1,869,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Ariadne Wealth Management LP boosted its position in Amgen by 8.7% during the 4th quarter. Ariadne Wealth Management LP now owns 922 shares of the medical research company’s stock worth $302,000 after buying an additional 74 shares during the period. Brown Advisory Inc. raised its holdings in Amgen by 1.4% during the 4th quarter. Brown Advisory Inc. now owns 122,302 shares of the medical research company’s stock worth $40,031,000 after purchasing an additional 1,704 shares during the last quarter. Bollard Group LLC raised its holdings in Amgen by 0.8% during the 4th quarter. Bollard Group LLC now owns 3,961 shares of the medical research company’s stock worth $1,296,000 after purchasing an additional 30 shares during the last quarter. Atlas Capital Advisors Inc. bought a new position in Amgen during the 4th quarter worth approximately $2,201,000. Finally, Aptus Capital Advisors LLC raised its holdings in Amgen by 0.6% during the 4th quarter. Aptus Capital Advisors LLC now owns 44,671 shares of the medical research company’s stock worth $14,621,000 after purchasing an additional 284 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Wall Street Zen upgraded shares of Amgen from a “hold” rating to a “buy” rating in a report on Sunday. Canaccord Genuity Group assumed coverage on shares of Amgen in a report on Monday, April 20th. They set a “hold” rating and a $366.00 price target for the company. The Goldman Sachs Group set a $389.00 price target on shares of Amgen in a report on Friday, June 5th. Leerink Partners restated a “market perform” rating and set a $355.00 price target on shares of Amgen in a report on Thursday, March 5th. Finally, UBS Group raised their price target on shares of Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Amgen currently has a consensus rating of “Hold” and a consensus target price of $354.12.

Amgen Stock Performance

NASDAQ:AMGN opened at $350.53 on Tuesday. The company has a fifty day moving average of $341.03 and a 200-day moving average of $345.86. The firm has a market capitalization of $189.18 billion, a P/E ratio of 24.39, a P/E/G ratio of 3.56 and a beta of 0.42. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. Amgen Inc. has a twelve month low of $267.83 and a twelve month high of $391.29.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. Amgen’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 22.38 EPS for the current year.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.85% of the company’s stock.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.